Company profile: Atrin Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical discovery and development for innovative cancer treatments. The privately held company, based in Doylestown, PA, is engaged in the discovery and development of treatments for cancer, with its most advanced program focused on a new class of highly specific compounds.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atrin Pharmaceuticals
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Fusion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fusion Pharmaceuticals company profile →
Precision Biologics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic and diagnostic products for the early detection and treatment of cancer, including monoclonal antibody drug candidates NEO-201 and Ensituximab (NEO-102), companion diagnostics (IHC and serum ELISA) to predict and monitor patient response, and clinical trials evaluating the efficacy of their therapeutic antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision Biologics company profile →
Photocure
HQ: United States
Website
- Description: Provider of photodynamic specialty pharmaceuticals, including Hexvix/Cysview to improve bladder tumor detection and resection via Blue Light Cystoscopy, and Cevira, a photodynamic drug-device for non-surgical treatment of cervical HSIL; also supports patient registries and real-world evidence in bladder cancer. Norwegian-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Photocure company profile →
Cullinan Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics, including zipalertinib (CLN-081/TAS6417) for NSCLC with EGFR exon 20 insertion mutations in pivotal Phase 2b; CLN-619, an anti-MICA/B antibody tested with a checkpoint inhibitor for advanced solid tumors and multiple myeloma; CLN-049 for relapsed/refractory AML and MDS in Phase 1; and CLN-617, a collagen-binding IL-12/IL-2 fusion for advanced solid tumors, both as monotherapy and in combination with pembrolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullinan Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atrin Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atrin Pharmaceuticals
2.2 - Growth funds investing in similar companies to Atrin Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atrin Pharmaceuticals
4.2 - Public trading comparable groups for Atrin Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →